<table border="0" cellpadding="1" cellspacing="0" id="Table_5" xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4 Drug Interactions: Changes in Pharmacokinetic Parameters for Co-administered Drug in the Presence of Nevirapine (All interaction trials were conducted in HIV-1 positive subjects)</caption>
<colgroup>
<col valign="top"></col>
<col valign="top"></col>
<col valign="top"></col>
<col valign="top"></col>
<col valign="top"></col>
<col valign="top"></col>
<col valign="top"></col>
</colgroup>
<thead>
<tr>
<th align="left" stylecode="Toprule Botrule Lrule">Co-administered Drug</th>
<th align="left" stylecode="Toprule Botrule Lrule">Dose of Co-administered Drug</th>
<th align="left" stylecode="Toprule Botrule Lrule">Dose Regimen of Nevirapine</th>
<th align="left" stylecode="Toprule Botrule Lrule">n</th>
<th align="left" colspan="3" stylecode="Toprule Botrule Lrule Rrule">% Change of Co-administered Drug Pharmacokinetic Parameters (90% CI)</th>
</tr>
</thead>
<tfoot>
<tr>
<td colspan="7">§ = C<sub>min</sub> below detectable level of the assay<br/> ↑ = Increase, ↓ = Decrease, ⇔ = No Effect<br/>
<sup>a</sup> For information regarding clinical recommendations, <content stylecode="italics">see Drug Interactions (<linkhtml href="#Section_7">7</linkhtml>)</content>.<br/>
<sup>b</sup> Pediatric subjects ranging in age from 6 months to 12 years <br/>
<sup>c</sup> Parallel group design; n for nevirapine+lopinavir/ritonavir, n for lopinavir/ritonavir alone.<br/>
<sup>d</sup> Parallel group design; n=23 for atazanavir/ritonavir + nevirapine, n=22 for atazanavir/ritonavir without nevirapine. Changes in atazanavir PK are relative to atazanavir/ritonavir 300/100 mg alone.<br/>
<sup>e</sup> Based on between-trial comparison.<br/>
<sup>f</sup> Based on historical controls.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td colspan="4" stylecode="Toprule Rrule Lrule">
<content stylecode="bold">
<content stylecode="emphasis">Antiretrovirals</content>
</content>
</td>
<td stylecode="Toprule Rrule">
<content stylecode="bold">
<content stylecode="emphasis">AUC</content>
</content>
</td>
<td stylecode="Toprule Rrule">
<content stylecode="bold">
<content stylecode="emphasis">C<sub>max</sub>
</content>
</content>
</td>
<td stylecode="Toprule Rrule">
<content stylecode="bold">
<content stylecode="emphasis">C<sub>min</sub>
</content>
</content>
</td>
</tr>
<tr>
<td rowspan="2" stylecode="Toprule RRule LRule">Atazanavir/Ritonavir<sup> a, d</sup>
</td>
<td rowspan="2" stylecode="Toprule RRule">300/100 mg QD<br/>day 4 to 13, then 400/100 mg QD, day 14 to 23</td>
<td rowspan="2" stylecode="Toprule RRule">200 mg BID day 1 to 23. Subjects were treated with nevirapine prior to trial entry.</td>
<td rowspan="2" stylecode="Toprule RRule">23</td>
<td stylecode="TopRule RRule">
<content stylecode="underline">Atazanavir<br/>300/100 mg</content>
<br/>
<br/> ↓42<br/> (↓52 to ↓29)<br/>
<br/>
</td>
<td stylecode="TopRule RRule">
<content stylecode="underline">Atazanavir<br/> 300/100 mg <br/>
</content>
<br/> ↓28<br/> (↓40 to ↓14)<br/>
<br/>
</td>
<td stylecode="Toprule RRule">
<content stylecode="underline">Atazanavir<br/> 300/100 mg <br/>
</content>
<br/> ↓72<br/> (↓80 to ↓60)<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="TopRule RRule">
<content stylecode="underline">Atazanavir<br/> 400/100 mg<br/>
</content>
<br/> ↓19<br/> (↓35 to ↑2)<br/>
<br/>
</td>
<td stylecode="TopRule RRule">
<content stylecode="underline">Atazanavir<br/> 400/100 mg<br/>
</content>
<br/> ↑2<br/> (↓15 to ↑24)<br/>
<br/>
</td>
<td stylecode="TopRule RRule">
<content stylecode="underline">Atazanavir<br/> 400/100 mg<br/>
</content>
<br/> ↓59 <br/> (↓73 to ↓40)<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="TopRule RRule LRule">Darunavir/Ritonavir <sup>e</sup>
</td>
<td stylecode="TopRule RRule">400/100 mg BID</td>
<td stylecode="TopRule RRule">200 mg BID</td>
<td stylecode="TopRule RRule">8</td>
<td stylecode="TopRule RRule">↑24 <br/> (↓3 to ↑57)<br/>
<br/>
</td>
<td stylecode="TopRule RRule">↑40 <br/> (↑14 to ↑73)<br/>
<br/>
</td>
<td stylecode="TopRule RRule">↑2 <br/> (↓21 to ↑32)<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Didanosine</td>
<td stylecode="Toprule Rrule">100 to 150 mg BID</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">18</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">§</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Efavirenz<sup>a</sup>
</td>
<td stylecode="Toprule Rrule">600 mg QD</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 400 mg QD x 14 days</td>
<td stylecode="Toprule Rrule">17</td>
<td stylecode="Toprule Rrule">↓28<br/> (↓34 to ↓14)</td>
<td stylecode="Toprule Rrule">↓12<br/> (↓23 to ↑1)</td>
<td stylecode="Toprule Rrule">↓32<br/> (↓35 to ↓19)</td>
</tr>
<tr>
<td stylecode="TopRule RRule LRule">Fosamprenavir</td>
<td stylecode="TopRule RRule">1400 mg BID</td>
<td stylecode="TopRule RRule">200 mg BID.  Subjects were treated with nevirapine prior to trial entry.</td>
<td stylecode="TopRule RRule">17</td>
<td stylecode="TopRule RRule">↓33 <br/> (↓45 to ↓20)<br/>
<br/>
</td>
<td stylecode="TopRule RRule">↓25 <br/> (↓37 to ↓10)<br/>
<br/>
</td>
<td stylecode="TopRule RRule">↓35  <br/> (↓50 to ↓15)<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="TopRule RRule LRule">Fosamprenavir/Ritonavir</td>
<td stylecode="TopRule RRule">700/100 mg BID</td>
<td stylecode="TopRule RRule">200 mg BID.  Subjects were treated with nevirapine prior to trial entry</td>
<td stylecode="TopRule RRule">17</td>
<td stylecode="TopRule RRule">↓11<br/> (↓23 to ↑3)<br/>
<br/>
</td>
<td stylecode="TopRule RRule">⇔<br/>
<br/>
</td>
<td stylecode="TopRule RRule">↓19 <br/> (↓32 to ↓4)<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Indinavir<sup>a</sup>
</td>
<td stylecode="Toprule Rrule">800 mg q8H</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">19</td>
<td stylecode="Toprule Rrule">↓31<br/> (↓39 to ↓22)</td>
<td stylecode="Toprule Rrule">↓15<br/> (↓24 to ↓4)</td>
<td stylecode="Toprule Rrule">↓44<br/> (↓53 to ↓33)</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Lopinavir<sup>a, b</sup>
</td>
<td stylecode="Toprule Rrule">300/75 mg/m<sup>2</sup> (lopinavir/<br/> ritonavir) <sup>b</sup>
</td>
<td stylecode="Toprule Rrule">7 mg/kg or 4 mg/kg QD x 2 weeks; BID x 1 week</td>
<td stylecode="Toprule Rrule">12, 15 <sup>c</sup>
</td>
<td stylecode="Toprule Rrule">↓22<br/> (↓44 to ↑9)</td>
<td stylecode="Toprule Rrule">↓14<br/> (↓36 to ↑16)</td>
<td stylecode="Toprule Rrule">↓55<br/> (↓75 to ↓19)</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Lopinavir<sup>a</sup>
</td>
<td stylecode="Toprule Rrule">400/100 mg BID (lopinavir/ritonavir)</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID &gt;1 year</td>
<td stylecode="Toprule Rrule">22, 19 <sup>c</sup>
</td>
<td stylecode="Toprule Rrule">↓27<br/> (↓47 to ↓2)</td>
<td stylecode="Toprule Rrule">↓19<br/> (↓38 to ↑5)</td>
<td stylecode="Toprule Rrule">↓51<br/> (↓72 to ↓26)</td>
</tr>
<tr>
<td stylecode="TopRule RRule LRule">Maraviroc <sup>f</sup>
</td>
<td stylecode="TopRule RRule">300 mg SD</td>
<td stylecode="TopRule RRule">200 mg BID</td>
<td stylecode="TopRule RRule">8</td>
<td stylecode="TopRule RRule">↑1 <br/> (↓35 to ↑55)</td>
<td stylecode="TopRule RRule">↑54 <br/> (↓6 to ↑151)</td>
<td stylecode="TopRule RRule">⇔ </td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Nelfinavir<sup>a</sup>
</td>
<td stylecode="Toprule Rrule">750 mg TID</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">23</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">↓32<br/> (↓50 to ↑5)</td>
</tr>
<tr>
<td stylecode="Rrule Lrule">Nelfinavir-M8 metabolite</td>
<td stylecode="Rrule"> </td>
<td stylecode="Rrule"> </td>
<td stylecode="Rrule"> </td>
<td stylecode="Toprule Rrule">↓62<br/> (↓70 to ↓53)</td>
<td stylecode="Toprule Rrule">↓59<br/> (↓68 to ↓48)</td>
<td stylecode="Toprule Rrule">↓66<br/> (↓74 to ↓55)</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Ritonavir</td>
<td stylecode="Toprule Rrule">600 mg BID</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">18</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">⇔</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Stavudine</td>
<td stylecode="Toprule Rrule">30 to 40 mg BID</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">22</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">§</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Zalcitabine</td>
<td stylecode="Toprule Rrule">0.125 to 0.25 mg TID</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">6</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">§</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Zidovudine</td>
<td stylecode="Toprule Rrule">100 to 200 mg TID</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">11</td>
<td stylecode="Toprule Rrule">↓28<br/> (↓40 to ↓4)</td>
<td stylecode="Toprule Rrule">↓30<br/> (↓51 to ↑14)</td>
<td stylecode="Toprule Rrule">§</td>
</tr>
<tr>
<td colspan="4" stylecode="Toprule Rrule Lrule">
<content stylecode="bold">
<content stylecode="emphasis">Other Medications</content>
</content>
</td>
<td stylecode="Toprule Rrule">
<content stylecode="bold">
<content stylecode="emphasis">AUC</content>
</content>
</td>
<td stylecode="Toprule Rrule">
<content stylecode="bold">
<content stylecode="emphasis">C<sub>max</sub>
</content>
</content>
</td>
<td stylecode="Toprule Rrule">
<content stylecode="bold">
<content stylecode="emphasis">C<sub>min</sub>
</content>
</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Clarithromycin<sup>a</sup>
</td>
<td stylecode="Toprule Rrule">500 mg BID</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">15</td>
<td stylecode="Toprule Rrule">↓31<br/> (↓38 to ↓24)</td>
<td stylecode="Toprule Rrule">↓23<br/> (↓31 to ↓14)</td>
<td stylecode="Toprule Rrule">↓56<br/> (↓70 to ↓36)</td>
</tr>
<tr>
<td stylecode="Rrule Lrule">Metabolite <br/> 14-OH-clarithromycin</td>
<td stylecode="Rrule"> </td>
<td stylecode="Rrule"> </td>
<td stylecode="Rrule"> </td>
<td stylecode="Toprule Rrule">↑42<br/> (↑16 to ↑73)</td>
<td stylecode="Toprule Rrule">↑47<br/> (↑21 to ↑80)</td>
<td stylecode="Toprule Rrule">⇔</td>
</tr>
<tr>
<td rowspan="2" stylecode="Toprule Rrule Lrule">Ethinyl estradiol<sup>a</sup>
<br/>
<br/> and<br/>
<br/> Norethindrone<sup>a</sup>
</td>
<td stylecode="Toprule Rrule">0.035 mg<br/> (as Ortho-Novum<sup>®</sup> 1/35)</td>
<td rowspan="2" stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td rowspan="2" stylecode="Toprule Rrule">
<br/>10</td>
<td stylecode="Toprule Rrule">↓20<br/> (↓33 to ↓3)</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">§</td>
</tr>
<tr>
<td stylecode="Rrule">1 mg<br/> (as Ortho-Novum<sup>®</sup> 1/35)</td>
<td stylecode="Toprule Rrule">↓19<br/> (↓30 to ↓7)</td>
<td stylecode="Toprule Rrule">↓16<br/> (↓27 to ↓3)</td>
<td stylecode="Toprule Rrule">§</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Depomedroxy-progesterone acetate</td>
<td stylecode="Toprule Rrule">150 mg every 3 months</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">32</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">⇔</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Fluconazole</td>
<td stylecode="Toprule Rrule">200 mg QD</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">19</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">⇔</td>
<td stylecode="Toprule Rrule">⇔</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Ketoconazole<sup>a</sup>
</td>
<td stylecode="Toprule Rrule">400 mg QD</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">21</td>
<td stylecode="Toprule Rrule">↓72<br/> (↓80 to ↓60)</td>
<td stylecode="Toprule Rrule">↓44<br/> (↓58 to ↓27)</td>
<td stylecode="Toprule Rrule">§</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Methadone<sup>a</sup>
</td>
<td stylecode="Toprule Rrule">Individual Subject Dosing</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID ≥7 days</td>
<td stylecode="Toprule Rrule">9</td>
<td colspan="3" stylecode="Toprule Rrule">In a controlled pharmacokinetic trial with 9 subjects receiving chronic methadone to whom steady-state nevirapine therapy was added, the clearance of methadone was increased by 3-fold, resulting in symptoms of withdrawal, requiring dose adjustments in 10 mg segments, in 7 of the 9 subjects. Methadone did not have any effect on nevirapine clearance.</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Rifabutin<sup>a</sup>
</td>
<td stylecode="Toprule Rrule">150 or 300 mg QD</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">19</td>
<td stylecode="Toprule Rrule">↑17<br/> (↓2 to ↑40)</td>
<td stylecode="Toprule Rrule">↑28<br/> (↑9 to ↑51)</td>
<td stylecode="Toprule Rrule">⇔</td>
</tr>
<tr>
<td stylecode="Rrule Lrule">Metabolite<br/> 25-O-desacetyl-rifabutin</td>
<td stylecode="Rrule"> </td>
<td stylecode="Rrule"> </td>
<td stylecode="Rrule"> </td>
<td stylecode="Toprule Rrule">↑24<br/>(↓16 to ↑84)</td>
<td stylecode="Toprule Rrule">↑29<br/> (↓2 to ↑68)</td>
<td stylecode="Toprule Rrule">↑22<br/> (↓14 to ↑74)</td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule Botrule">Rifampin<sup>a</sup>
</td>
<td stylecode="Toprule Botrule Rrule">600 mg QD</td>
<td stylecode="Toprule Botrule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Botrule Rrule">14</td>
<td stylecode="Toprule Botrule Rrule">↑11<br/> (↓4 to ↑28)</td>
<td stylecode="Toprule Botrule Rrule">⇔</td>
<td stylecode="Toprule Botrule Rrule">§</td>
</tr>
</tbody>
</table>